How Can We Help?
Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by Pharco Pharmaceuticals) in clinical trials for chronic hepatitis C genotype 4.[1]
It is on the World Health Organization's List of Essential Medicines.[2]
Preliminary clinical trial results were announced in Nov 2015.[3] In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt.[4] It has been granted conditional registration by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.[5][6]
References
- ^ Clinical trial number NCT02371408 for "Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4" at ClinicalTrials.gov
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ^ "Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4". Hepatitis Magazine. 24 November 2015.
- ^ Kollewe J (13 April 2018). "Non-profit's $300 hepatitis C cure as effective as $84,000 alternative". The Guardian.
- ^ "List of new products approved by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia" (PDF).
- ^ "First hepatitis C treatment developed through South-South cooperation registered in Malaysia | DNDi". dndi.org. 14 June 2021. Retrieved 10 August 2021.
Recent Comments